Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …

Simple Summary AML is a genetically heterogeneous disease with a median age of
diagnosis between 60 and 70 years. Thus, many AML patients are not eligible for intensive …

Acute myeloid leukemia (AML) is a heterogenous and complex disease characterized by
rapid cellular proliferation, an aggressive clinical course, and generally high mortality. While …

Abstract Treatment of relapsed or refractory acute myeloid leukemia (AML) has presented
challenges for hematologists for decades. Despite numerous clinical studies, outcomes are …

Introduction: Acute myeloid leukemia (AML) is a deadly disease associated with poor
outcomes. For over four decades, therapeutic options for AML were limited to high dose …

Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease.
Despite advances in understanding the pathogenesis of AML, the standard therapy …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an
incidence that increases with age, and a generally poor prognosis. The disease is clinically …

The standard therapy for acute myeloid leukemia (AML) has not changed meaningfully for
the past four decades. Improvements in supportive care and modifications to the dose and …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that
has a poor prognosis. Recent advances in genomics and molecular biology have led to a …